)
Exact Sciences (EXAS) investor relations material
Exact Sciences AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key officers present.
Inspector of Election confirmed and agenda, rules of conduct, and Q&A procedures outlined.
Shareholder proposals
Three proposals presented: approval of merger agreement, advisory vote on executive compensation related to the merger, and potential adjournment to solicit more proxies.
Q&A with stakeholders
Stockholders could submit questions online, limited to one per person, with follow-up promised for unanswered questions.
Updates provided on regulatory approvals (expected completion before end of Q2 2026) and reference to SEC filings for merger-related litigation.
- Multi-cancer early detection could cut late-stage cancer by 40% and mortality by 18%.EXAS
7th Annual Healthcare Symposium - International expansion accelerates with new products, offices, and integration with Abbott.EXAS
Proxy Filing - Record revenue, improved cash flow, and major merger plans mark a transformative year.EXAS
Q4 2025 - Merger with Abbott at $105 per share prompts supplemental disclosures and litigation response.EXAS
Proxy Filing - Q2 revenue up 12% to $699M; record test volumes and raised EBITDA guidance.EXAS
Q2 2024 - Cologuard Plus and a robust pipeline position the company for sustained growth and market leadership.EXAS
Jefferies Global Healthcare Conference - All proposals passed, with director elections, auditor ratification, and no shareholder questions.EXAS
AGM 2024 - Cologuard Plus, automation, and global expansion fuel strong growth and margin gains.EXAS
Goldman Sachs 45th Annual Global Healthcare Conference - Growth driven by innovation, digital integration, and organizational agility, with guidance reaffirmed.EXAS
The 44th Annual William Blair Growth Stock Conference
)
)
)
)
)
)
)
)